Radiation-induced lung damage promotes breast cancer lung-metastasis through CXCR4 signaling by Feys, Lynn et al.
Oncotarget26615www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol.6, NO. 29
Radiation-induced lung damage promotes breast cancer lung-
metastasis through CXCR4 signaling
Lynn Feys1, Benedicte Descamps2, Christian Vanhove2, Anne Vral3, Liv Veldeman4, 
Stefan Vermeulen5, Carlos De Wagter4, Marc Bracke1 and Olivier De Wever1
1 Department of Radiation Oncology and Experimental Cancer Research, Laboratory of Experimental Cancer Research, Ghent 
University, Ghent, Belgium
2 Department of Electronics and Information System, iMinds-IBiTech-MEDISIP, Ghent University, Ghent, Belgium
3 Department of Basic Medical Sciences, Physiology Group, Ghent University, Ghent, Belgium
4 Department of Radiation Oncology and Experimental Cancer Research, Gent University Hospital, Ghent, Belgium
5 Department of Biomedical Science, HoGent, Ghent, Belgium
Correspondence to: Olivier De Wever, email: Olivier.dewever@ugent.be
Keywords: radiotherapy, triple-negative breast cancer, CXCL12, MIF, AMD3100
Received: July 22, 2015 Accepted: August 29, 2015 Published: September 15, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Radiotherapy is a mainstay in the postoperative treatment of breast cancer as 
it reduces the risks of local recurrence and mortality after both conservative surgery 
and mastectomy. Despite recent efforts to decrease irradiation volumes through 
accelerated partial irradiation techniques, late cardiac and pulmonary toxicity still 
occurs after breast irradiation. The importance of this pulmonary injury towards lung 
metastasis is unclear. Preirradiation of lung epithelial cells induces DNA damage, 
p53 activation and a secretome enriched in the chemokines SDF-1/CXCL12 and 
MIF. Irradiated lung epithelial cells stimulate adhesion, spreading, growth, and 
(transendothelial) migration of human MDA-MB-231 and murine 4T1 breast cancer 
cells. These metastasis-associated cellular activities were largely mimicked by 
recombinant CXCL12 and MIF. Moreover, an allosteric inhibitor of the CXCR4 receptor 
prevented the metastasis-associated cellular activities stimulated by the secretome 
of irradiated lung epithelial cells. Furthermore, partial (10%) irradiation of the right 
lung significantly stimulated breast cancer lung-specific metastasis in the syngeneic, 
orthotopic 4T1 breast cancer model. 
Our results warrant further investigation of the potential pro-metastatic effects 
of radiation and indicate the need to develop efficient drugs that will be successful 
in combination with radiotherapy to prevent therapy-induced spread of cancer cells.
INTRODUCTION
Postoperative radiotherapy reduces the risk of 
both recurrence and mortality of breast cancer, and is 
nowadays standard treatment in the management of breast 
cancer after conservative surgery and after mastectomy 
to anticipate the high risk of relapse [1, 2]. Despite this 
progress, locoregional post radiotherapy relapses still 
occur in about 7-12.6% of the patients within the 5 
years after treatment [3-5]. Relapses occurring within a 
preirradiated area are associated with an increased risk of 
local invasion, metastasis formation and poor prognosis 
compared to relapses occurring outside of the irradiated 
area [6]. Recent experimental evidence supports these 
clinical observations. In murine xenograft models, tumors 
developing within preirradiated beds are more invasive 
and metastatic compared to tumors growing outside 
irradiated beds, a condition also referred to as “tumor bed 
effect”. Kuonen et al. investigated cellular and molecular 
mechanisms underlying the tumor bed effect in breast 
cancer by using the 4T1 triple-negative murine model 
mimicking local relapse after radiotherapy and identified 
the role of cancer cells and mobilized myeloid cells as 
a metastasis promoting mechanism in breast [7]. Also, 
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radiation-induced stemness of residual breast cancer cells 
increased spontaneous lung metastasis [8].
Although these experimental models adequately 
address the impact of the local tumor bed effect, these 
in vivo models do not consider the incidental exposure 
of the cardiopulmonary region to ionizing radiation after 
postoperative radiotherapy. Incidental cardiopulmonary 
irradiation is clinically important since it increases the 
subsequent rate of ischemic heart disease and secondary 
lung cancer risk [9, 10]. Radiotherapy regimens for breast 
cancer have changed since these trials; the doses of up to 
15 Gy to which the cardiopulmonary region was exposed 
are now generally lower [9, 10]. Nevertheless, in most 
women receiving contemporary radiotherapy protocols, 
the cardiopulmonary region receives doses of 1 to 10.9 
Gy [11]. The estimated percentage of total irradiated lung 
volume may range from 2.7 to 17.6% in a study population 
receiving tangential radiation beams [12].
Lungs are a prime target organ for breast cancer 
metastasis but the impact of incidental radiation 
exposure on lung metastasis is unknown. In this paper, 
we experimentally and molecularly addressed whether 
preirradiation of lung epithelial cells impacts metastasis-
associated cellular activities of well-characterized triple-
negative human MDA-MB-231 and murine 4T1 breast 
cancer cells. Using a murine xenograft model, lung 
metastasis formation was evaluated after exposure of 10% 
volume of the right lung to clinically relevant doses of 
radiation.
RESULTS
Radiation effects on damage response 
and senescence markers in normal lung 
microenvironments
To assess treatment-induced damage response in 
normal cells of the lung microenvironment, we examined 
mouse lung tissue that was excised 15 minutes after 
receiving thoracic sham or 10 Gy irradiation. We found 
evidence of DNA damage in lung epithelial cells as 
determined by the phosphorylation of histone H2AX on 
Ser139 (γH2AX) within 15 minutes after 10 Gy irradiation 
(Figure 1A). To further ascertain the consequence of 
DNA damage in benign cells, we established an in 
vitro model treating Beas-2B epithelial cells of the lung 
microenvironment with a 10 Gy single radiation dose 
which substantially increased the number of γH2AX 
foci (Figure 1B). Irradiated cells showed no increase in 
cell death (Figure 1C, lower panel), but showed a more 
spread morphology with enlarged nuclei and increased 
cytoplasmic surface area (Figure 1C, upper panel). 
Furthermore, activation of p53 and increased expression 
of the p21 cell cycle arrest protein were observed (Figure 
1D, Supplementary Figure S1). An indicator of cellular 
senescence, p21, was maintained up to 4 days after 
irradiation, which explains the lower number of cells 
(Figure 1B, 1C and 1D).
Impact of irradiated lung epithelial cells on breast 
cancer cell growth and adhesion
Irradiated or sham-irradiated Beas-2B cells were 
grown in co-culture with 4T1_luc or MDA-MB-231GFP_
luc triple-negative breast cancer cells and cancer cell 
growth was monitored by measuring luciferase activities 
after 4 days of co-culture. Co-culture with irradiated 
Beas-2B cells significantly enhanced the relative cancer 
cell growth 1.7-and 2.8-fold respectively compared to co-
culture with unirradiated Beas-2B cells (4T1_luc: sham 
vs. 10 Gy: 1.000 ± 0.030 vs. 1.740 ± 0.172; P < 0.001; 
MDA-MB-231GFP_luc: sham vs. 10 Gy: 1.000 ± 0.067 
vs. 2.806 ± 0.203; P < 0.001) (Supplementary Figure S2A, 
Figure 2A). 
To study the effect on cancer cell adhesion, we 
seeded breast cancer cells on a monolayer of Beas-
2B epithelial cells 24 hours after irradiation or sham-
irradiation. Co-culture with irradiated Beas-2B cell 
monolayer significantly increased adhesion of both cancer 
cells 1.7-and 1.3-fold respectively compared to co-culture 
with unirradiated Beas-2B cell monolayer (4T1_luc: sham 
vs. 10 Gy: 1.000 ± 0.068 vs. 1.66 ± 0.3211; P < 0.001; 
MDA-MB-231GFP_luc: sham vs. 10 Gy: 1.000 ± 0.182 
vs. 1.328 ± 0.210; P < 0.001) (Supplementary Figure S2B, 
Figure 2B).
Impact of soluble factors derived from irradiated 
lung epithelial cells on breast cancer cell 
morphology, growth, migration and extravasation
To further investigate these effects we collected 
conditioned medium of unirradiated (CMLE) and irradiated 
Beas-2B cells (CMLE_IR). Incubation of 4T1_luc and 
MDA-MB-231GFP_luc cells with CMLE_IR significantly 
increased relative cell growth 1.8-and 1.9-fold respectively 
compared to incubation with CMLE (Supplementary Figure 
S2C, Figure 2C) (CMLE vs. CMLE_IR; 4T1_luc: 1.000 ± 
0.314 vs. 1.800 ± 0.730; P < 0.001; MDA-MB-231GFP_
luc: 1.001 ± 0.159 vs. 1.891 ± 0.569; P < 0.001). 
F-Actin staining of single cells revealed a more 
elongated morphology upon CMLE_IR compared to CMLE 
(Figure 2D, lower panel). This is shown by an increase 
in mean factor shape of MDA-MB-231GFP_luc cells 
incubated with CMLE_IR, this was 2.2-fold higher compared 
to the CMLE condition (CMLE vs. CMLE_IR: 3.742 ± 1.686 vs. 
8.240 ± 2.197; P < 0.001) (Figure 2D, upper panel).
Morphological changes suggest an impact on the 
migratory potential of cells. To investigate the effect of 
irradiated epithelial cells on breast cancer cell migration 
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Figure 1: Lung epithelial cells radiation response and senescence markers. A. Immunohistochemical (IHC) staining of 
ɣH2AX foci using an immunoenzymatic DAB staining method (brown color) combined with a haematoxylin counterstaining in sham or 
10 Gy irradiated mouse lung tissue. B. Immunocytochemical (ICC) staining of ɣH2AX foci (Alexa488 labeled secondary antibody, green 
color) combined with a DAPI nuclear counterstaining (blue color) in sham or 10 Gy irradiated Beas-2B lung epithelial cells. C. Upper 4 
panels, phase contrast micrographs of Beas-2B lung epithelial cells two or four days post sham or 10 Gy irradiation. The 10 Gy condition 
shows less dense cell culture, a more spread cell morphology with enlarged nuclei and increased cytoplasmic surface area. Lower 2 panels, 
live/dead - viability/cytotoxicity test. Assay shows live cells as green and dead cells as red. Four days after single irradiation dose of 10 Gy 
shows no increase of Beas-2B cell death. D. Western blot (WB) analysis of p53 and p21 on total cell lysates from Beas-2B cells treated with 
single-fraction 10 Gy or sham. Total p53 expression is unchanged after irradiation but increase in p53 phosphorylation is observed at day 1 
after treatment and normalizes at day 4. Total expression of p21 is increased until day 4. GAPDH and tubulin are used as loading control.
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Figure 2: Impact of irradiated lung epithelial cells on breast cancer cell adhesion and growth. A. Box plots illustrating 
the relative cell growth of MDA-MB-231GFP_luc cells. Co-culture of breast cancer with irradiated Beas-2B cells increases relative cell 
growth compared to co-culture with sham treated Beas-2B cells. Quantification by bioluminescent imaging after 4 days incubation. Data 
is represented as relative fold change compared with the corresponding control value. MDA-MB-231GFP_luc: n = 6; ***, P < 0.001 
(Unpaired t-test with Welch’s correction). B. Box plots illustrating the relative cell adhesion of MDA-MB-231GFP_luc cells. Relative 
Adhesion of breast cancer cells to irradiated Beas-2B cell monolayer is increased compared to sham treated Beas-2B cell monolayer. 
Quantification by bioluminescent imaging after 24 hours incubation. Data is represented as relative fold change compared with the 
corresponding control value. MDA-MB-231GFP_luc: n = 15; ***, P < 0.0001; circle = outlier (Unpaired t-test with Welch’s correction). 
Impact of CMLE_IR on breast cancer cell morphology, growth, migration and extravasation. C. Box plots illustrating the relative cell growth 
of MDA-MB-231GFP_luc cells. Treatment of breast cancer cells with CMLE_IR increases relative cell growth compared to cells treated 
with CMLE. Quantification by bioluminescent imaging after 4 days incubation. Data is represented as relative fold change compared with 
the corresponding control value (CMLE). MDA-MB-231GFP_luc: n = 21; ***, P < 0.001 (Mann-Whitney U). D. Box plots illustrating 
the extent of cell spreading of MDA-MB-231GFP_luc cells in CMLE_IR versus CMLE conditions, as quantified by factor shape (upper 
panel). Treatment with CMLE_IR showed enhanced cell spreading, corresponding with the significantly altered cell shapes (lower panel).
Fluorescence microscopy images of cells double stained with phalloidin for actin filaments (red) and DAPI counterstaining for nuclei (blue) 
after 4 days of incubation with CMLE_IR versus CMLE. n = 20; ***, P < 0.001 (Mann-Whitney U). E. Box plots illustrating total migrated cell 
number of MDA-MB-231GFP_luc cells in CMLE_IR versus CMLE conditions (upper panel). Nuclei of migrated cells were stained blue by 
DAPI (lower panel). n = 12; ***, P < 0.001 (Unpaired t-test with Welch’s correction). F. Box plots illustrating total migrated cell number 
of MDA-MB-231GFP_luc cells through endothelial monolayer in CMLE_IR versus CMLE conditions (upper panel). CMLE_IR enhances breast 
cancer cell extravasation significantly. Endothelial cells were stained red with Vibrant DiI. Extravasated MDA-MB-231GFP_luc cells are 
green (lower panel). n = 6; **, P = 0.0022 (Mann-Whitney U). Arrowheads indicating GFP positive migrated breast cancer cells.
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we employed TransWell® culture chambers separated into 
two compartments by microporous filters. In the lower 
compartment CMLE or CMLE_IR was added, while on top 
MDA_MB-231GFP_luc cells were seeded. As shown in 
Figure 2E, the directed migration of MDA-MB-231GFP_
luc cells was significantly increased by 3.4-fold in the cells 
in presence of CMLE_IR compared to those of CMLE (CMLE 
vs. CMLE_IR: 49.46 ± 18.52 cells vs. 166.70 ± 60.75 cells; 
P < 0.001).
Extravasation, the migration of cancer cells through 
the endothelial wall into the target parenchyma, is another 
critical step in metastasis. This functional activity was 
biomimicked by studying directed breast cancer cell 
migration to CMLE or CMLE_IR through a monolayer of 
endothelial cells. Under CMLE_IR conditions 4.7-fold more 
MDA-MB-231GFP_luc migrated through the endothelial 
layer compared to CMLE conditions (CMLE vs. CMLE_IR: 
52.00 ± 39.69 cells vs. 243.70 ± 57.25 cells; P = 0.002) 
(Figure 2F, Arrowheads in CMLE point to migrated cancer 
cells.). 
Summarized, we have shown that the secretome of 
irradiated Beas-2B lung epithelial cells contains factors 
that reorganize breast cancer cells to a more elongated 
shape and increase growth, migration and extravasation 
of the cancer cells.
Figure 3: Increased secretion of CXCL12 and MIF by irradiated lung epithelial cells. A. Cytokine array identifies enhanced 
presence of CXCL12 and MIF in CMLE_IR compared to CMLE. B. ELISA analysis of CXCL12 (upper panel) and MIF (lower panel) on 
CMLE_IR versus CMLE. For each condition 2 different samples were used in triplicate. Values are presented as the mean ± SD. CXCL12: **, 
P = 0.010. MIF: **, P = 0.004 (Mann-Whitney U). C. Western blot analysis of CXCR4 expression on total lysate of breast cancer cells. 
Lane 1-5, represents MDA-MB-231GFP_luc (invasive cell line) in different conditions (MDA 231: parental MDA-MB-231GFP_luc; MDA 
231 I4 D4: MDA 231 cells exposed to CMLE_IR for 4 days; MDA 231 C4 D4: MDA 231 cells exposed to CMLE for 4 days; MDA 231 RL 
0 Gy: MDA 231 isolated from non-irradiated mouse lung; MDA 231 RL 10 Gy: MDA 231 isolated from irradiated mouse lung. Lane 6: 
SKBR3 (non-invasive cell line). Lane 7: MDA-MB-231H2N (invasive cell line). Lane 8: MDA-MB-453 (invasive cell line). Lane 9: MCF 
10A (non-invasive cell line). Lane 10: MCF7/6 (non-invasive cell line). D. Quantitative analysis CXCR4 protein expression level. Western 
blot analysis of CXCR4 protein expression in different breast cancer cell lines after tubulin normalization. Protein levels relative to control, 
MDA-MB-231GFP_luc.
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Increased secretion of CXCL12 and MIF by 
irradiated lung epithelial cells
The composition of CMLE and CMLE_IR was 
assessed to determine which cytokines were secreted 
by unirradiated versus irradiated lung epithelial cell. 
Semi-quantitative results from a cytokine array showed 
that CMLE_IR contained a total of 52 cytokines with a 
signal that exceeded that of CMLE condition (Figure 3A; 
Supplementary Table S1). We selected the CXCL12 and 
MIF cytokines for further study because of a high fold 
change (more than 80-fold) and a known role in breast 
cancer metastasis [13]. CXCL12 and MIF, which had 
an 83.88-and 86.46-fold higher presence, respectively, 
in CMLE_IR compared to CMLE (Supplementary Table 1). 
Responding to fold changes (relative changes) rather than 
absolute change is intrinsically important in chemokine 
attraction and consequently regulation of metastasis [14, 
15]. Quantitative ELISA data showed that irradiated lung 
epithelial cells had a secretion of CXCL12 and MIF that 
is 5.8-and 7.9-fold higher, respectively, than unirradiated 
lung epithelial cells (Figure 3B) (CMLE vs. CMLE_IR; 
CXCL12: 61.07 ± 12.59 vs. 353.70 ± 126.00 pg/mL/106 
cells/24h; P = 0.010; MIF: 1.072 ± 0.390 vs. 8.495 ± 0.695 
ng/mL/106 cells/24h; P = 0.004). According to previous 
literature, both cytokines may affect metastasis through 
activation of the CXCR4 receptor on cancer cells [13]. 
Western Blot analysis confirmed that cancer cell lines, that 
are known to have an invasive phenotype, have a higher 
expression of CXCR4 (45-47 kDa) (Figure 3C-3D)[16].
Effect of recombinant CXCL12 and MIF on 
breast cancer cell growth and migration
To verify if CXCL12 and MIF may contribute to the 
effects observed with the secretome of irradiated cells, the 
recombinant forms were supplemented to the secretome of 
unirradiated cells and used to assess the functional impact 
on cancer cells. CMLE supplemented with recombinant 
CXCL12 or MIF induced an increase in cell growth as 
demonstrated for MDA-MB-231GFP_luc cells (Figure 
4A) (CMLE vs. CMLE + CXCL12: 1.002 ± 0.157 vs. 1.807 
± 0.241; P < 0.001; CMLE vs. CMLE + MIF: 1.002 ± 0.157 
vs. 2.010 ± 0.259; P < 0.001) and induced an increase in 
cell migration after treatment with CXCL12 (Figure 4B) 
(CMLE vs. CMLE + CXCL12: 48.830 ± 18.640 vs. 82.830 ± 
29.360; P = 0.038). Experiments with MIF did not show 
significant difference in cancer cell migration (data not 
shown).
Allosteric targeting of CXCR4 receptor reversed 
paracrine effect induced by irradiated epithelial 
cells
To investigate whether the observed effects depend 
on activation of the CXCR4 receptor, AMD3100, an 
allosteric inhibitor of CXCR4 receptor, was used. Addition 
of AMD3100 reversed the pro-metastasis associated 
effects of CMLE_IR such as relative cell growth (Figure 
5A) (CMLE_IR vs. CMLE_IR + AMD3100: 1.000 ± 0.107 vs. 
0.717 ± 0.144; P < 0.001 ), relative adhesion (Figure 5B) 
(CMLE_IR vs. CMLE_IR + AMD3100: 1.000 ± 0.060 vs. 0.665 
± 0.166; P < 0.001), migration and extravasation of breast 
cancer cells (Figure 5C & 5D) (Migration - CMLE_IR vs. 
CMLE_IR + AMD3100: 162.40 ± 74.62 cells vs. 75.33 ± 
33.32 cells; P = 0.009;Extravasation - CMLE_IR vs. CMLE_IR 
+ AMD3100: 243.70 ± 57.25 cells vs. 100.40 ± 57.11 cells; 
P = 0.017). Furthermore, AMD3100 treatment partially 
reversed CMLE_IR -induced morphological changes, as 
measured by factor shape (Figure 5E) (CMLE_IR vs. CMLE_IR 
+ AMD3100: 8.240 ± 2.197 vs. 5.243 ± 2.772; P = 0.004).
Paracrine activation of ERK, Akt and STAT3 in 
breast cancer cells by CMLE_IR and recombinant 
CXCL12
CMLE_IR activated multiple CXCR4-dependent 
downstream cascades, like ERK, Akt and STAT3, 
in MDA-MB-231GFP_luc cells (Figure 6A). These 
pathways are involved in mediating cellular proliferation, 
survival, migration, transformation and differentiation 
[17]. In agreement, addition of recombinant CXCL12 or 
MIF stimulated Akt, ERK and STAT3 activation, although 
an equal concentration of MIF showed a smaller increase 
than CXCL12 (Figure 6A, Supplementary Figure S3A).
Next, we examined the impact of Trametinib and 
AMD3100 on CMLE_IR-induced ERK, Akt and STAT3 
activation. Previous literature showed that triple-negative 
breast cancer cells are the most sensitive for treatment 
with MEK inhibitor[18]. Nanomolar concentrations of 
Trametinib, an allosteric MEK1/2 inhibitor, completely 
blocked CMLE_IR induced ERK activation (Figure 6B, 
Supplementary Figure S3B) with no impact on AKT or 
STAT3 activation. Similar effects were observed when 
combining recombinant CXCL12 or MIF with Trametinib 
(Figure 6C-6D, Supplementary Figure S3C-D). In 
accordance with the functional experiments, AMD3100 
decreased CMLE_IR-induced Akt and STAT3 pathway 
activation; a minor impact on pERK was observed in 
the cancer cells exposed with CMLE_IR + AMD3100 
compared to CMLE_IR alone (Figure 6B). These effects with 
AMD3100 are less pronounced when CMLE is combined 
with recombinant CXCL12 and MIF (Figure 6C-6D, 
Supplementary Figure S3C-D). 
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Impact of partial lung irradiation on lung-specific 
breast cancer metastasis in a syngeneic mouse 
model
A syngeneic, orthotopic triple-negative breast cancer 
model 4T1_luc was developed to study the impact of 
irradiation of the lung on the formation of lung metastasis. 
Patient studies showed that approximately 10% of the total 
lung volume is irradiated during breast cancer RT, with 
a mean lung dose of 10 Gy [11, 12]. All groups of mice 
received CT scan radiation for the localization of lung 
tissue; in the sham treatment group, no further irradiation 
was performed; the WT group received a 10 Gy irradiation 
to the whole thorax; the PRL group (partial right lung) 
received a 10 Gy irradiation to approximately 18mm3 part 
(10% of total volume) of the right lung (Supplementary 
Figure S4-S5). 4T1_luc cells (1 x 106) were orthotopically 
injected 24 hours after irradiation. Neither WT nor PRL 
irradiation did significantly impact primary tumor growth 
(Figure 7A) (sham vs. 100% IR vs. 10% IR: 446 ± 111 
mm3 vs. 471 ± 63 mm3 vs. 526 ± 109 mm3). Four weeks 
after orthotopic 4T1_luc breast cancer inoculation, all 
lungs were prelevated and bioluminescent activity in the 
Figure 4: Effect of recombinant CXCL12 and MIF on breast cancer cell growth and migration. A. Box plots illustrating 
the relative cell growth of MDA-MB-231GFP_luc cells. Treatment of breast cancer cells with CXCL12 (50 ng/mL) or MIF (50 ng/mL) 
increases relative cell growth compared to control. Quantification by bioluminescent imaging after 4 days incubation. Data is represented 
as relative fold change compared with the corresponding control value (CMLE). n = 6; ***, P < 0.001 (Unpaired t-test). B. Box plots 
illustrating difference in total migrated cell number of MDA-MB-231GFP_luc cells treated with CXCL12 (50 ng/mL) (upper panel). Nuclei 
of migrated cells were stained blue with DAPI (lower panel). n = 6; *, P = 0.038 (Unpaired t-test). 
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Figure 5: Effect of an allosteric CXCR4 inhibitor on breast cancer cell growth and migration. A. Box plots illustrating 
the relative cell adhesion of MDA-MB-231GFP_luc cells. Treatment of breast cancer cells with AMD3100 (10 µM) decreases relative cell 
adhesion to irradiated Beas-2B cell monolayer. n = 12; ***, P < 0.001(Unpaired t-test with Welch’s correction). B. Box plots illustrating the 
relative cell growth of MDA-MB-231GFP_luc cells. Treatment of breast cancer cells with AMD3100 (10 µM) decreases relative cell growth 
in presence of CMLE-IR. (Unpaired t-test with Welch’s correction). n = 15; ***, P < 0.001 (Unpaired t-test). In C. and D., quantification 
by bioluminescent imaging after 4 days incubation. Data is represented as relative fold change compared with the corresponding control 
value. C. Box plots illustrating impact of AMD3100 (10 µM) on total migrated cell number of MDA-MB-231GFP_luc cells stimulated by 
CMLE-IR. Nuclei were stained blue with DAPI (lower panel). n = 9; **, P = 0.009 (Unpaired t-test with Welch’s correction). D. Box plots 
illustrating total transendothelial migrated cell number of MDA-MB-231GFP_luc cells stimulated by CMLE-IR in presence of AMD3100 (10 
µM) or control. n = 6; *, P = 0.017 (Mann-Whitney U). E. Box plots illustrating the extent of CMLE-IR -induced cell spreading of MDA-MB-
231GFP_luc cells treated with AMD3100 (10 µM) versus control, as quantified by factor shape (upper panel). Fluorescence microscopy 
images of cells double stained with phalloidin for actin filaments (red) and DAPI counterstaining for nuclei (blue) (lower panel). n = 20; 
**, P = 0.004 (Mann-Whitney U).
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Figure 6: Paracrine activation of ERK, Akt and STAT3 in breast cancer cells by CMLE_IR and recombinant CXCL12. 
A.-D.. Western blot analysis of pERK, pAkt and pSTAT3 in MDA-MB-231GFP_luc cells treated with recombinant CXCL12 (50 ng/mL) 
or MIF (50 ng/mL) A. CMLE, CMLE_IR, in presence of AMD3100 (10 µM) or Trametinib (50 nM) B. recombinant CXCL12 (50 ng/mL) C. 
or MIF (50 ng/mL) D. in presence of AMD3100 (10 µM) or Trametinib (50 nM) Tubulin is used as loading control.
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separate lungs was compared between the three groups. 
Mice which received a 10 Gy PRL irradiation showed 
more bioluminescent signal, and thus more metastasis, in 
each lung compared to WT irradiated or sham treated mice 
(Figure 7B). In addition, when only bioluminescent signal 
of those lungs with activity were included we observed 
significantly higher signals in the right lung of PRL 
irradiated mice compared to the right lung of sham treated 
mice, suggesting more metastatic growth (P = 0.043) 
(Figure 7C, Supplementary Figure S6); a similar trend 
was observed for the left lung but no significant value 
was reached. Semi-quantitative histological examination 
of metastatic lung tissue demonstrated more and larger 
metastasis in mice receiving PRL irradiation compared 
to sham or WT (Figure 7D, as illustration. Figure 7E, 
quantification). This was confirmed by quantitatively 
analyzing the total metastatic area between the groups. 
In sham groups an average metastatic area of 1.2% was 
reached, comparable to the WT irradiated group with an 
average area of 1.3%. Both groups are remarkably, but not 
significantly, lower than the PRL irradiated group, with a 
three-fold increase of metastatic area (5.0%) (Figure 7E). 
Moreover, comparing total lung bioluminescent signal 
(signal right and left lung as one), sham treated mice still 
had the lowest signal but WT irradiated mice and PRL 
irradiated mice showed a 2.1- and 7.1-fold increase, 
respectively, in signal (Figure 7F). 
DISCUSSION
Because of the absence of oestrogen-, progesterone- 
and HER2 receptor [19], triple-negative breast cancers are 
not curable with hormonal treatment and HER2 therapies. 
Standard mastectomy or breast conserving surgery with 
adjuvant radio-and chemotherapy is used as a standard to 
treat this patients [20]. Postoperative radiotherapy of breast 
cancer reduces the risk of local recurrence and mortality 
after both conservative surgery and mastectomy [1, 2]. 
Despite recent efforts to decrease irradiation volumes 
and improved irradiation techniques, late cardiac and 
pulmonary toxicity does still occur after breast irradiation 
[6, 11]. The implications of this pulmonary injury for 
lung metastasis are unclear. A randomized trial in high-
risk post-mastectomy patients showed that the long-term 
probabilities of lung metastases are significantly lower in 
the irradiated (RT) patients compared to non-irradiated 
(no-RT) patients. Interestingly, distant metastasis as 
first failure (independent from local relapse) was 47% 
in the RT group compared to 37% in the no-RT group, 
suggesting that lung metastasis do not necessarily occur 
after local relapse [21]. Although it is generally assumed 
in this case that micro-metastasis in the lungs were present 
before breast cancer was treated, an alternative, admittedly 
provocative, hypothesis is that radiation-induced collateral 
damage of the lung influences lung-specific metastasis. 
Metastasis can be an early event and stay undetected at 
time of diagnosis [22, 23]. Patients, presenting with micro-
metastasis, receive radiotherapy which can stimulate 
metastatic growth. The difference in our in vivo model is 
that we first irradiated the lung and waited for metastasis 
to grow [22]. Our model is not relevant for the effect of 
ionizing radiation on already established micro-metastasis 
because we graft syngeneic breast cancer cells after 
ionizing radiation. We radiate part of the right lung, graft 
syngeneic breast cancer cells and study the impact on 
spontaneous lung metastasis formation. Lung irradiation 
has no impact on orthotopic tumor growth. However, we 
observe more and bigger metastatic foci in the lungs of 
PRL mice which can be caused by increased attraction of 
circulating cancer cells and/or stimulation of cancer cell 
release from the primary tumor and/or preparation of the 
metastatic niche (promoting adhesion and colonization of 
breast cancer cells). Breast cancer patients who did receive 
post-mastectomy radiotherapy showed most often distant 
metastasis as first site of failure in contrast to patients 
who did not receive post-mastectomy radiotherapy, here 
locoregional relapse and distant metastasis as first site of 
failure were equally common [21]. Studies (using post-
mortem samplings) should be designed to investigate a 
potential relationship between collateral lung irradiation-
damage and lung metastasis in breast cancer patients. 
The literature provides no level-one evidence because 
no randomized trials have been done correlating the dose 
indices of irradiated lung volumes with lung-specific 
metastasis in breast cancer. A clinical study with breast 
cancer patients undergoing postoperative radiation 
therapy of 50 Gy at 2 Gy/fraction, 5 days/week showed 
that the pulmonary region received a mean lung dose of 
approximately 10 Gy. If more than 3 axillary lymph nodes 
were affected, a supraclavicular field was added with 
equal dose and fractionation resulting in a higher mean 
pulmonary dose of 15.8 Gy [11]. This collateral irradiation 
to the lungs resulted in reduced pulmonary function in the 
first two years after the postoperative radiotherapy. 
Histone H2AX phosphorylation is a recognized 
marker of DNA damage, i.e. double strand breaks [24]. 
The manner how DNA responds to radiation damage, 
indicated by γH2AX foci, has been investigated in 
mice models receiving thoracic radiation and shown to 
be correlative with fibrosis in distressed mice [25]. In 
our experiments, sham-irradiated lung tissue sections 
of BALB/c mice were almost completely negative for 
γH2AX foci, whereas 10 Gy thoracic irradiation resulted 
in a massive increase in the number of pulmonary 
nuclei with γH2AX foci throughout the tissue sections, 
irrespective of cell type. In vitro experimentation on lung 
epithelial cells, the major pulmonary cell type, revealed 
potent H2AX and p53 responses to radiation which 
coincided with morphological changes, induction of 
cellular senescence markers and an enhanced secretion 
of multiple chemokines and growth factors. Gunjal et al. 
demonstrated that ovarian cancer cells responding to heat-
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Figure 7: Impact of partial lung irradiation on lung-specific breast cancer metastasis in a syngeneic mouse model. A. 4 
week old BALB/c female mice were injected orthotopically with 1 x 106 4T1_luc cells in 0.1 mL of serum free DMEM with 50% Matrigel. 
Tumor formation was monitored for 28 days by caliper measurement. Tumor volumes were measured as indicated. Sham and WT IR: n 
= 6 and PRL: n = 5. B.-C. & F. 28 days after implantation of the cells, mice were sacrificed and total lung metastasis was quantified by 
bioluminescent imaging. Lung were quantified separately (B & C) or as one (F). Sham and WT: LL and RL, n = 6 and PRL: LL and RL, 
n = 5 (B). Only lungs containing metastasis were quantified, showing significant increase in signal in right lung of PRL mice. Sham: LL, 
n = 5; RL, n = 4; WT: LL, n = 4; RL, n = 5; PRL: LL, n = 4; RL, n = 4; *; P = 0.043 (Man-Whitney U test) (C). D. H&E staining of lungs 
from indicated groups. The metastatic areas are encircled (black). E. Quantification of the percentage of lung metastatic area calculated per 
mouse. Sham and WT: n = 6 and PRL: n = 5.
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sensitive chemoattractants released from irradiated organs, 
including the lung, are more migratory and metastatic 
[26]. Our in vitro irradiation experiment confirmed the 
increased release of CXCL12 and MIF upon irradiation. 
The heat-sensitive chemokines CXCL12 and MIF, both 
known to promote breast cancer metastasis, showed 
the highest fold change in secretion by irradiated lung 
epithelial cells compared to control, which was confirmed 
in our study [13, 27]. The irradiation caused induction of 
a metastasis-receptive microenvironment that promotes 
trafficking and homing of cancer cells to the lung [17, 
27-30]. Once the cells arrive in the lung, increased levels 
of CXCL12 and MIF retain the breast cancer cells in 
lung and provides it with survival and growth factors, so 
metastatic growth is enhanced [31-35]. It is not known 
whether CXCL12 and MIF are increased in lungs of 
irradiated breast cancer patients but future research could 
investigate the sputum, serum or urine of breast cancer 
patients in the acute or long-term response to radiation. 
Müller and co-workers were the first to demonstrate 
CXCR4-mediated metastasis of breast cancer cells to 
CXCL12-rich environments, like bone marrow, brain, 
lungs and liver [13]. Elevated CXCR4 expression in breast 
cancer cells negatively correlates with overall survival 
and disease-free survival in breast cancer patients and is 
correlated with malignant breast stem cell activity [36, 
37]. Targeting this pathway could thus be a promising 
therapeutic addition to radiotherapy. To investigate this, 
we used an allosteric inhibitor of CXCR4, AMD3100 
or Plerixafor®. AMD3100 was originally developed for 
HIV treatment and is nowadays used in combination with 
G-CSF as a stem cell mobilizer in patients with multiple 
myeloma and lymphoma [9, 13, 38-40]. Our co-culture 
findings showed that treatment of breast cancer cells with 
AMD3100 blocks the functional and biochemical effects 
induced by the secretome of irradiated epithelial cells. 
Nevertheless, the toxic effects of AMD3100 in long-term 
treatment limits its clinical potential [41]. However, Peng 
et al. identified a small cyclic peptide (LY2510924) that 
inhibits CXCL12 and CXCR4 interaction and downstream 
signaling and function [42]. Currently, this peptide is 
included in clinical trials on patients with advanced 
cancer [43]. The CXCL12 analog peptide CTCE-9908 
inhibits lung metastasis in mouse models [44, 45] and tests 
in Phase I/II clinical trials in cancer patients showed no 
major adverse effects [46]. Furthermore, the anti-CXCL12 
aptamer NOX-A12 inhibits brain tumor recurrences after 
irradiation in rats [47]. Potentially favorable collateral 
inhibition of the CXCR4-CXCL12 axis may prevent lung 
fibrosis, improving the quality of life in breast cancer 
patients [48]. 
We are not the first to report radiotherapy-
stimulated relapse in preclinical models. Ohuchida et al. 
reported that irradiation of stromal pancreatic fibroblast 
increased invasiveness of pancreatic cancer cell by 
upregulating c-Met phosphorylation and MAPK activity 
[49]. Irradiation of mouse embryo fibroblasts stimulates 
cancer cell repopulation in cell culture and xenograft 
models [50]. This effect is lost when the fibroblasts are 
deficient for caspase-3, a key executioner of programmed 
cell death. Moreover, radiotherapy is not unique in 
inducing pro-metastatic effects in preclinical models. 
Comparative analysis of matched colorectal cancer 
specimens shows that neoadjuvant chemotherapy results 
in increased presence of pro-invasive α-SMA-positive 
CAFs (cancer associated fibroblast) [51]. Monnier et al. 
demonstrated that after irradiation of the stromal bed, oral 
squamous cell carcinomas showed increased invasion and 
metastasis through the matricellular protein CYR61 [52]. 
Irradiation also has an effect on VEGF production and 
local angiogenesis, which finally contributes to metastasis 
formation [53].
Our results warrant further investigation of the 
potential pro-metastatic effects of radiation and indicate 
the need to develop efficient drugs which can be combined 
efficiently with RT in order to prevent therapy-induced 
spread of cancer cells. Nevertheless, the most efficient and 
simple solution is to prevent normal tissue irradiation. In 
breast cancer, the cardiopulmonary region can be spared 
of high doses by using multi-beam intensity-modulated 
radiotherapy or arc techniques, but often at the cost of a 
low dose spread [54]. Irradiating the breast when patients 
are in prone instead of supine position has been shown to 
spectacularly improve all lung dose-volume indices [55, 
56].
METHODS AND MATERIALS
Cell lines
EA.hy926, a human endothelial cell line was 
obtained from ATCC (Manassas, VA, USA). MDA-MB-
231GFP_luc, a human triple-negative breast cancer cell 
line [57]. 4T1_luc, a mouse triple-negative breast cancer 
cell was obtained from Sibtech (Brookfield, CT, USA). 
Beas-2B cell line, a human normal lung epithelial cell line, 
was kindly provided by Prof. K. De Bosscher (Cytokine 
Receptor Lab, VIB, Ghent University). EA.hy926, MDA-
MB-231GFP_luc, and 4T1_luc cells were maintained 
in DMEM culture medium supplemented with 10% 
fetal bovine serum, 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen, Waltham, MA, USA), and 2.5 
µg/mL fungizone (Bristol-Myers, Squibb, Belgium). 
Beas-2B cells were maintained in MEM culture medium 
supplemented with 0,05% L-glutamine (w/v), 10% 
fetal bovine serum, 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen), and 2.5 µg/mL fungizone. 
EA.hy926, 4T1_luc and Beas-2B were incubated with 5% 
CO2. MDA-MB-231GFP_luc cells were incubated with 
10% CO2. Authenticity of ATCC cell lines was confirmed 
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by short tandem repeat profiling in the last 6 months 
before use. Cell cultures were tested for mycoplasma 
contamination monthly by using MycoAlert Plus Kit 
(Lonza, Basel, Switzerland). MDA-MB-231GFP_luc, GFP 
expression was continuously induced with doxycycline 
(500 ng/mL, Sigma-Aldrich, St.Louis, MO, USA). 4T1_
luc were selected with Zeocine (500 µg/mL, Invitrogen).
Antibodies and reagents
Primary and secondary antibodies and reagents are 
described in Supplementary Materials and Methods. 
Conditioned medium of irradiated and 
unirradiated bronchial epithelial cells
Normal lung epithelial cells were cultured in a 25 
cm2 culture flask. Cells were irradiated using a Small 
Animal Radiation Research Platform, SARRP system 
(X-ray tube:ISOVOLT 225M2 X-ray source; SARRP 
system, XStrahl®, Surrey, UK) at a constant rate of 3.45 
Gy/min, for 174 seconds, thus receiving a single-fraction 
of 10.0 Gy (220 kV and 13.0 mA, using an 0.15 mm 
cupper filter and a 10 x 10 cm collimator). Cells were 
positioned at a source-to-surface distance (SSD) of 34 cm. 
Control “sham” samples (0 Gy) received similar handlings 
except for the irradiation. Conditioned medium containing 
soluble factors derived from irradiated epithelial cells 
(CMLE_IR) and medium of the sham epithelial cells (CMLE) 
was prepared as described in Supplementary Materials and 
Methods.
Quantification DNA double-strand breaks (DSB)
Quantification of ɣH2AX is used to quantify DSB. 
For the in vitro experiments on human Beas-2B lung 
epithelial cells a mouse monoclonal anti-ɣH2AX primary 
antibody was used in combination with an Alexa488-
conjugated rabbit anti-mouse secondary antibody and 
DAPI nuclear counterstain. The protocol as described 
in Depuydt et al. was followed [58]. For ɣH2AX foci 
analysis in the mouse lung tissue a rabbit polyclonal 
anti-ɣH2AX primary antibody was used in combination 
with a biotinylated goat anti-rabbit secondary antibody. 
To visualize the foci an immunoenzymatic staining using 
horse radish peroxidase-conjugated streptavidin and DAB 
was applied followed by haematoxylin counterstaining. 
The protocol as described in Bolcaen et al. was followed 
[59]. Mice were euthanized 15 minutes after receiving 
thoracic sham or 10 Gy irradiation.
Viability assay
The viability was analysed with the LIVE/DEAD 
kit for mammalian cells (Invitrogen), as described in 
Supplementary Materials and Methods.
Functional assays with direct cell-cell contacts
Cell growth assay. Beas-2B cells, cultured in 
DMEM with 10% FBS until 70% confluency, received 
a sham or 10 Gy radiation. After 24 hours 1 x 103 
MDA-MB-231GFP_luc or 4T1_luc cells were added to 
suspended and seeded together with 2 x 105 sham or 10 
Gy irradiated Beas-2B cells. After 4 days of co-culture, 
medium was changed and luciferine containing medium 
was added (150 µg/mL) 2 minutes before imaging. 
Imaging time was 2 min/cell plate. Light emitted from the 
breast cancer cells was detected by a highly sensitive CCD 
camera in the In Vivo Imaging System Lumina II (IVIS®, 
Caliper Life Science, Hopkinton, MA, USA). Analysis 
was achieved with Living Image® software (Caliper Life 
Science). There was a correlation between cell number 
and bioluminescence in vitro, using the In Vivo Imaging 
System (data not shown) [60].
Cell adhesion assay. To study the difference in 
adhesion of breast cancer cells to irradiated versus 
unirradiated epithelial cells, Beas-2B were cultured 
in a 6-well plate until confluency. The monolayer was 
sham or 10 Gy. 24 hours after treatment 2 x 104 MDA-
MB-231GFP_luc or 4T1_luc cells were added to the 
monolayers. To study the effect of AMD3100, a CXCR4 
antagonist, cancer cells were pretreated for 30 minutes 
with 10 µM AMD3100. In AMD3100 condition, 
pretreated cancer cells were added to the monolayer with 
a total AMD3100 concentration of 10 µM. Adhesion was 
analyzed after 24 hours using IVIS as described above.
Functional assays with conditioned media
Cell growth assay. MDA-MB-231GFP_luc and 
4T1_luc cells (2 x 104) were seeded in a 24-well plate 
and treated either with CMLE_IR or CMLE. To study the 
effect of recombinant CXCL12 or MIF on cancer cell 
growth, cells were treated with CMLE supplemented with 
MIF or CXCL12 (50 ng/mL). The effect of an inhibitor 
was studied by pretreatment of the cancer cells with 10 
µM AMD3100 for 30 minutes and a total AMD3100 
concentration of 10 µM in CMLE_IR. After 4 days cell 
numbers were analyzed by bioluminescent signal detection 
as described above.
Migration assay. MDA-MB-231GFP_luc cells 
(1 x 105 cells) were plated in the upper compartment of 
a Transwell chamber (24-well insert, pore size 8 μm, 
Corning Incorporated, New York, NY), while in the lower 
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compartment CMLE_IR, CMLE or CMLE supplemented with 
CXCL12 (50 ng/mL) was used as a chemoattractant. To 
study the effect of AMD3100, cancer cells were pretreated 
30 minutes with 10 µM AMD3100, and AMD3100 was 
added in both compartments in CMLE_IR with a final 10 
µM concentration. Migration was stopped after 8 hours 
incubation and the insert was washed with PBSD+. Cells 
from the apical side were removed using a cotton swab 
before fixation with ice-cold methanol and DAPI staining. 
After 4 washing steps with PBSD-, the filter was mounted 
onto glass using glycergel mounting medium (Dako, 
Carpinteria, CA, USA). Cell nuclei were analyzed by 
counting 6 different, randomly chosen fields with a 
10x objective on a Zeiss Axiovert 200M fluorescent 
microscope.
Transendothelial migration assay. Formation 
and analysis of endothelial monolayer is described in 
Supplementary Materials and Methods and Supplementary 
Figure S7.
Doxycycline-induced MDA-MB-231GFP_luc 
cells (1 x 105) were added on top of the endothelial cells. 
CMLE_IR, CMLE or CMLE_IR + AMD3100 were used as a 
chemoattractant. After incubation for 24 hours the apical 
side of the chamber was washed twice with PBSD+ and 
scraped gently with a cotton swap. Migrated cancer cells, 
green fluorescent, were counted from 8 different, randomly 
chosen fields with a 10x objective on a Zeiss Axiovert 
200M fluorescent microscope (Carl Zeiss, Micro-imaging, 
Heidelberg, Germany).
Morphology analysis. For quantification of 
morphological changes, 2 x 105 MDA-MB-231GFP_luc 
single cells were seeded on glass cover slips in presence 
of control medium or CMLE_IR. After 4 days of incubation, 
cells were fixed with 3.7% formaldehyde for 20 minutes. 
Permeabilization with 0,1% Triton-X100 was done for 
5 minutes and cells were blocked for 30 minutes, while 
shaking, with 1% BSA. Next, glasses were stained with 
F-actin stain phalloidin-Alexa Fluor 594 and DAPI 
and imaged with a Zeiss Axiovert 200M fluorescent 
microscope. Of each condition, 20 cells from 4 different 
glasses were used to score factor shape with the formula: 
(perimeter)2/(4 x π x area).
Protein analysis
SDS-PAGE and Western blot analysis. Lysate 
preparation, SDS-PAGE and Western blot analysis are 
described in Supplementary Materials and Methods.
Cytokine array. RayBio®Label-Based human 
antibody array 507 (L-507, RayBiotech Inc., Norcross, 
GA, USA) was used to identify the cytokines playing a key 
role in the effect of irradiated bronchial epithelial cells. 
Cytokine array analysis is described in Supplementary 
Materials and Methods.
ELISA analysis. CXCL12 and MIF secretion levels 
were measured using quantitative immunometric sandwich 
enzyme immunoassays (ELISA = enzyme-linked 
immunosorbent assay), following the manufacturer’s 
recommended procedures (R & D Systems, Minneapolis, 
MN, USA). Optical density was measured at 450 nm 
of wavelength, with correction set to 570 nm, on a 
PARADIGM™ Microplate Detection Platform (Beckman 
Coulter, Brea, CA, USA). Triplicate cultures of cells were 
tested for each experimental condition. 
Animal studies
Radiotherapy treatment planning. In this study, 
two different dose plans were set up and executed on the 
SARRP. One delivered 10Gy to the entire thorax, the other 
delivered 10 Gy to 10% volume of the right lung. First, 
dose distributions was calculated using the on-board CT 
as described earlier [61]. 4-week-old BALB/c female mice 
(Charles River, L’Abresle, France), were anesthetized, 
fixed on a plastic bed and placed on a holder secured 
onto the robotic positioning table. Cone-beam (CB) CT 
imaging is achieved by rotating the stage that supports the 
animal, horizontally between the stationary X-ray source 
and a flat-panel detector. The uncollimated primary beam, 
20 cm × 20 cm at isocenter, is used for imaging. X-rays 
of 70 kV emitted from the 0.4 mm focal spot and filtered 
by 1 mm thick aluminum were employed. Images were 
acquired at a current of 1 mA, with “continuous” beam-
on as well as “continuous” stage rotation. Three hundred 
and sixty (360) projections were acquired over 360°. 
Second, the treatment isocenter was placed in the lower 
part of the right hemisphere of the lung. For whole thorax 
treatment, two posterior-anterior beams, with a size of 9 
x 3 mm and 10 x 10mm at isocenter, were used to cover 
the entire thorax (Supplementary Figure S5B). Treatment 
isocenter was set for both in the middle of both lungs. 
One posterior-anterior beam with a size of 3 x 3 mm 
was selected to irradiate 18 mm3 of the right lung with 
10 Gy, which resembles approximately 10% volume of 
the right lung (8,57% calculation based on Knuts et al. 
[62]) (Supplementary Figure S5A, S5C). The CT scans 
are imported into Muriplan software (Xstrahl®). Next, 
image intensity-based tissue segmentation was performed 
to allow correct dose calculation throughout the different 
tissue densities. The voltage of the X-ray source is fixed 
at 220 kV with a tube current of 12 mA, emitted from 
the 3.0 mm focal spot and filtered by a copper filter of 
0.15 mm. Mice with sham treatment only underwent the 
imaging part.
4T1_luc triple-negative mouse breast cancer 
model. All mice were orthotopically injected 24 hours 
after radiation treatment. One million 4T1_luc cells, 
suspended in a 100 µL mixture of serum-free DMEM 
and Matrigel (1:1), were injected into the mammary 
fat pad. The primary tumor volume was quantified as 
the product of caliper measurements of the longest 
and the shortest tumor diameter (V = 0,4 x (longest 
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axis) x (shortest axis)2). Primary and metastatic tumor 
growths were monitored by bioluminescence. First, 
mice were giving an intraperitoneaal injection of 100 µL 
D-luciferin in PBS (150 µg/g mouse). Then, animals were 
anesthetized with 5% isoflurane in oxygen for induction 
and 1.5% isoflurane in oxygen for maintenance. Next, 
bioluminescent imaging was initiated 10 minutes after 
injection by a cooled CCD camera in the IVIS with a 15-
cm field of view, binning factor of 8, 1/f stop and open 
filter. Exposure times were set automatically, depending 
on the luciferase signaling activity. ROIs were drawn for 
primary tumor and metastatic lesions and were calculated 
by the IVIS software, expressed in total flux (photon/s). 
Background photon flux was defined, for primary growth 
on a blanc mouse and for metastatic lesions on a normal 
lung, and extracted from all animal values. Images 
were initiated every 4 days after inoculation. After 4 
weeks, mice were sacrificed and tumor and lungs were 
resected. Lungs were placed into 6-well plates and ex vivo 
bioluminescent imaging was performed by adding 300 
µg/mL D-luciferin in excess. After imaging, all tissues 
were fixed in 4% buffered formalin. H&E staining and 
immunohistochemistry were performed using a NexES 
automated slide staining system (Ventana Medical 
Systems, Tucson, AZ) on paraffin sections. Animals were 
treated according to the European guidelines on animal 
experiments (2010/63/EU). They were kept in 12h light- 
dark cycles, with ad libitum access to food and water. 
Animal studies were approved by the Animal Ethics 
Committee of Ghent University, Belgium (ECD 10/36).
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism and confirmed by IBM SPSS Statistics 21.0 
software. D’Agostino-Pearson was used for testing normal 
distribution. Normal distributed data were analyzed using 
unpaired t-test, adjusted with Welch’s correction when 
variance was statistically different. All nonparametric data 
were analyzed using Mann-Whitney U test. All values in 
box- and whisker blots are expressed as the mean and 
95% confidence interval. All other values are expresses 
as the mean ± SD. A P value of < 0.05 was considered 
statistically significant. Statistical tests were two -sided. 
All data are representative of at least three independent 
experiments.
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Abbreviations
α-SMA:  Alfa smooth muscle actin
Akt: Protein kinase B
AMD3100:  1,1′-[1,4-Phenylenebis(methyl
ene)]bis[1,4,8,11-tetraazacyclotetradecane]
BALB:  Bagg Albino 
BSA:  Bovine serum albumin
CAF:  Cancer-associated fibroblast
CCD:  Charge coupled device
c-Met:  Cellular mesenchymal to epithelial 
transition factor
CMLE: Conditioned medium lung epithelial 
cells
CMLE-IR:  Conditioned medium irradiated lung 
epithelial cells
CT:  Computed tomography
CXCL12:  C-X-C chemokine ligand 12
CXCR4: C-X-C chemokine receptor 4 
CYR61:  Cysteine-rich angiogenic inducer 61
DAB: 3,3’-diaminobenzidine 
tetrahydrochloride hydrate
DAPI: 4’,6-diamidino-2-phenylindole
DiI:  1,1’-dioctadecyl-3,3,3’3’-
tetramethylindocarbocyanine perchlorate
DMEM:  Dulbecco’s Modified Eagle’s medium
DSB:  Double strand break 
ELISA:  Enzyme-linked immunosorbent assay
ERK:  Extracellular Signal-Regulated Kinase
GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase
G-CSF:  Granulocyte colony-stimulating factor
GFP: Green fluorescent protein
Gy: Unit of absorbed dose and equivalent to 
1 J/kg
H2AX:  Histone 2A, member X
IVIS:  In vivo imaging system  
MAPK: Mitogen-activated protein kinase
MEK1/2:  Mitogen-activated protein kinase/
extracellular signal-regulated kinase kinase 1/2
MIF:  Macrophage migration inhibitory factor
PBS D- :  Phosphate-buffered saline without 
calcium and magnesium
PBS D+:  Phosphate-buffered saline supplemented 
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with calcium and magnesium
PRL: Partial right lung
ROI:  Region of interest 
RT: Radiation treatment/Radiotherapy
SARRP:  Small animal radiation research 
platform
SD:  Standard deviation
SDF-1: Stromal cell-derived factor 1
SPSS:  Statistical package for the social science
STAT3:  Signal transducer and activator of 
transcription 3
WT:  Whole thorax
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